Testosterone Cypionate and Anesthesia: Perioperative Interaction Guide

Does testosterone cypionate interact with anesthetic drugs?

The drug interaction section of the Depo-Testosterone (testosterone cypionate) label names three things: oral anticoagulants, oxyphenbutazone, and medicines used to treat diabetes [1]. Anesthetics are not among them [1].

What the label warns about that matters around surgery

Hematocrit and polycythemia

The cypionate label lists polycythemia as an adverse reaction and, for long-term use, says to check hemoglobin and hematocrit periodically [1].

How much does it rise? A network meta-analysis of 29 placebo-controlled randomized trials (3,393 men) found intramuscular testosterone enanthate or cypionate raised mean hematocrit by 4.0% over placebo (95% CI 2.9 to 5.1), compared with 3.0% for gel and 1.4% for patch [3]. A retrospective review of 178 hypogonadal men followed for 3 years reported erythrocytosis (hematocrit above 50%) in 66.7% of men on injectable testosterone, 12.8% on gels and 35.1% on pellets; the injectable group was younger (mean 42.5 vs about 54 years) with a higher starting hematocrit, and the comparison was not randomized [4].

Whether that translates into clots is less settled. One review found the erythrocytosis risk with testosterone therapy well established and highest with short-acting injectables, while the link to thromboembolic events remains unclear [5]. Another review put the risk of erythrocytosis (hematocrit above 0.52) at 315% higher than controls and called the erythrocytosis-VTE link inconclusive [6].

Blood clots

The label carries postmarketing reports of deep vein thrombosis and pulmonary embolism in people using testosterone products such as testosterone cypionate, and says to evaluate for DVT or PE and discontinue testosterone if an event is suspected [1]. In a UK case-control study of 19,215 men with confirmed venous thromboembolism and 909,530 matched controls, the adjusted rate ratio for VTE was 1.25 (95% CI 0.94 to 1.66) with current testosterone use, 1.63 (95% CI 1.12 to 2.37) in the first six months of treatment, and 1.00 (95% CI 0.68 to 1.47) after six months [7].

Blood pressure, fluid and calcium

The label says testosterone can increase blood pressure, which can increase cardiovascular risk over time, and directs that blood pressure be measured periodically; it also states that testosterone products are not recommended in patients with uncontrolled hypertension [1]. FDA's February 2025 class-wide labeling action said ambulatory blood pressure studies confirmed a blood pressure increase with all testosterone products [8].

Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal or hepatic disease [1]. Hypercalcemia may occur in immobilized patients, and the label says the drug should be discontinued if it does [1]. Serious cardiac, hepatic or renal disease is a contraindication to Depo-Testosterone [1].

On cardiovascular outcomes, the cypionate label still states that long-term safety trials have not been conducted and that studies have been inconclusive for major adverse cardiovascular events, with some but not all reporting an increased risk [1]. TRAVERSE randomized 5,246 men with hypogonadism and existing or high cardiovascular risk to daily 1.62% testosterone gel or placebo gel and found MACE in 7.0% versus 7.3% (hazard ratio 0.96, 95% CI 0.78 to 1.17) [9]. It tested a gel, not injections, and no outcome trial of that size exists for injectable testosterone [9].

Anticoagulants and glucose

Androgens may increase sensitivity to oral anticoagulants, and the label says the anticoagulant dose may require reduction in order to maintain satisfactory therapeutic hypoprothrombinemia [1]. The adverse reactions section also lists suppression of clotting factors II, V, VII and X, and bleeding in patients on concomitant anticoagulant therapy [1]. Androgens may also lower blood glucose and insulin requirements [1].

Dosing schedule and guideline

The labeled regimen is 50 to 400 mg every 2 to 4 weeks, injected deep into the gluteal muscle and never intravenously, with a half-life of about 8 days after intramuscular injection [1]. The Endocrine Society's 2018 guideline recommends against starting testosterone therapy in men with elevated hematocrit, uncontrolled heart failure, or a heart attack or stroke within the previous 6 months, and recommends monitoring hematocrit, serum testosterone and prostate cancer risk during the first year [10]. Those recommendations concern starting treatment.